GHRP-2, also called pralmorelin, is a synthetic hexapeptide in the growth hormone secretagogue class that prompts the anterior pituitary to release the body's own growth hormone in natural pulses rather than supplying synthetic hormone directly. The published record treats it as a research chemical, not an approved medicine: it holds no FDA marketing authorization for general use, is banned in competitive sport, and its long-term human safety data remain thin. What is well documented is the mechanism and the acute hormonal effect; the sweeping anti-aging and muscle-building claims that surround it are not.
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that stimulates pulsatile release of endogenous growth hormone and is sold in the United States as a research-use-only chemical with no FDA approval for general human use.
The record describes GHRP-2 as a six-amino-acid secretagogue that coaxes the gland into releasing its own growth hormone rather than replacing it, which is the distinction that matters for how it behaves. Its action is twofold: it activates the ghrelin receptor on the pituitary and hypothalamus while also blunting somatostatin, the brake on growth hormone release. Because the pituitary stays the source, the effect depends on a functioning gland and preserves the body's own feedback rhythm.
GHRP-2 raises growth hormone through two documented actions, agonism at the ghrelin (growth hormone secretagogue) receptor and suppression of somatostatin, producing a pulsatile release that depends on a functioning pituitary rather than replacing the hormone directly.
Nearly every effect attributed to GHRP-2 traces back to a single event, the growth hormone pulse it triggers and the IGF-1 that pulse raises in the liver. The literature draws a clear line between what is reliably shown, chiefly the growth hormone and IGF-1 rise and a pronounced appetite increase, and the anti-aging or dramatic muscle claims that circulate without controlled evidence.
The demonstrated effects of GHRP-2 are a reliable growth hormone and IGF-1 elevation and a pronounced ghrelin-mediated appetite increase, while its anti-aging and major muscle-building claims rest on extrapolation rather than controlled human evidence.
Because its half-life is short, published protocols describe GHRP-2 as several small subcutaneous doses spread across the day rather than one large one, imitating the body's repeated growth hormone pulses. The recurring reference point in that literature is the saturation dose, the amount at which the pituitary response effectively maxes out near one microgram per kilogram per administration. These handling conventions are documented topic knowledge for a research-use-only compound, not a protocol to follow, and no substitute for medical supervision.
Published GHRP-2 protocols describe divided subcutaneous doses near a saturation point of roughly one microgram per kilogram per administration, taken on an empty stomach with food delayed about twenty to thirty minutes, though the compound is not FDA-approved and these conventions are documentation rather than medical guidance.
The side-effect profile of GHRP-2 tracks the hormones it moves, and the most honest risk is what remains unstudied. Common short-term effects are mild and dose-related, but GHRP-2 specifically drives more cortisol and prolactin than cleaner secretagogues, and it has never completed the long-term human trials that would characterize its safety over years of use.
GHRP-2's side effects range from mild dose-related hunger and water retention to a distinctive cortisol and prolactin rise and unresolved long-term risks, including reduced insulin sensitivity and a theoretical concern that elevated growth hormone and IGF-1 could promote existing tumors, with no large long-term human safety trials completed.
GHRP-2 sits in a regulatory gray zone, and the defining fact about it is that it is not an approved drug. In the United States it has never received FDA marketing authorization and circulates as a research chemical labeled for research use only or not for human consumption, a boundary that sidesteps the approval and manufacturing standards required of medicines.
GHRP-2 holds no FDA marketing authorization and is sold in the United States as a research-use-only chemical rather than an approved medicine, and it is prohibited at all times in competitive sport by the World Anti-Doping Agency.
The choice between secretagogues is really a choice about tradeoffs, and GHRP-2 sits in the middle of the field. It delivers a strong, well-established pulse with moderate side effects, less selective than ipamorelin, less hunger-driving than GHRP-6, and less exhausting to the receptor than hexarelin.
| Criteria | GHRP-2 | GHRP-6 | Ipamorelin |
|---|---|---|---|
| GH pulse strength | Strong | Comparable, slightly less | Moderate |
| Appetite effect | Moderate | Intense | Minimal |
| Cortisol / prolactin | Elevated at higher doses | Elevated | Minimal |
GHRP-2 delivers a stronger growth hormone pulse than ipamorelin but with more cortisol, prolactin, and appetite effect, less hunger than GHRP-6, and less receptor desensitization than hexarelin, placing it as a moderate-side-effect middle option among growth hormone secretagogues.
The most common documented use of GHRP-2 is not alone but stacked with a growth hormone releasing hormone analog, most often CJC-1295, because the two act on separate receptors. CJC-1295 raises the pituitary's baseline readiness to release growth hormone while GHRP-2 delivers the sharp trigger, and fired together they produce a pulse substantially larger than either alone. That amplification also magnifies the load: water retention, blood-sugar shifts, and GHRP-2's cortisol and prolactin effects can all increase.
GHRP-2 is most commonly stacked with the GHRH analog CJC-1295 because the two act on separate receptors and together produce a growth hormone pulse larger than either alone, an amplification that also magnifies water retention, blood-sugar shifts, and GHRP-2's cortisol and prolactin effects.
The scientific record on GHRP-2 is real but narrower than its popularity suggests. Under the name pralmorelin it was studied seriously as a diagnostic agent, a challenge test for pituitary growth hormone secretion, but it has not accumulated the large, multi-year, placebo-controlled trials that would support confident claims about long-term performance, anti-aging, or body-composition use.
GHRP-2, as pralmorelin, is supported by controlled studies as a diagnostic growth hormone challenge test, but it lacks the large, multi-year, placebo-controlled trials needed to substantiate its marketed long-term performance, anti-aging, or body-composition claims.
GHRP-2 is a fast-acting, short-lived peptide, and its pharmacokinetics explain most of how it is used. A subcutaneous dose drives a growth hormone pulse that peaks within roughly fifteen to thirty minutes, while the peptide's own half-life runs about thirty minutes, so it clears well before the downstream IGF-1 it sets in motion.
GHRP-2 has a circulating half-life of roughly thirty minutes and drives a growth hormone pulse peaking near fifteen to thirty minutes after a subcutaneous dose, a short profile that is why protocols favor several small daily doses over one large one.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
